|
|
||||||||


* Department of Animal Sciences and Industry, Kansas State University, Manhattan 66506-0201
East Central Select Sires, Waupon, WI 53916
Select Sires, Plain City, OH 43064-0143
2 Corresponding author: jss{at}k-state.edu
| ABSTRACT |
|---|
|
|
|---|
Key Words: gonadotropin-releasing hormone human chorionic gonadotropin pregnancy survival progesterone
| INTRODUCTION |
|---|
|
|
|---|
In recent years, human chorionic gonadotropin (hCG) has been evaluated for its ability to improve fertility of cows and heifers through altered ovarian function. Human chorionic gonadotropin has activity similar to LH, is able to bind to tissue LH receptors, and mimics effects of LH by causing small luteal cells to increase P4 synthesis. When given early in the estrous cycle (d 3 to 5; d 0 = estrus), hCG can alter proportions of small and large luteal cells, thus potentially changing total P4 production by the CL, because approximately 80% of luteal P4 is derived from large luteal cells (Niswender et al., 2000). When administered during the midluteal phase (d 10 to 15), hCG alters duration of the estrous cycle (Eduvie and Seguin, 1982; Howard and Britt, 1990) and enhances endogenous concentrations of P4 (Schmitt et al., 1996; Santos et al., 2001) through luteotropic effects on the existing CL or by increasing the incidence of ovulation and accessory CL formation (Rajamahendran and Sianangama, 1992; Santos et al., 2001). In addition, luteal phase treatment with hCG after AI increased conception rates (Breuel et al., 1989; Santos et al., 2001).
Studies that administered exogenous progestins during the luteal phase after AI by applying P4-releasing intravaginal devices (PRID) for 7 d produced inconsistent effects on conception rates (Robinson et al., 1989; Stevenson and Mee, 1991). Concentrations of P4 in the former study were increased when cows were treated with PRID for 7 d between d 5 and 12 but not when treated between d 12 and 19 after AI. Conception rates of cows were improved, however, after treatments during either period of the luteal phase (Robinson et al., 1989). No increase in conception rates was detected when intra-vaginal controlled internal drug release (CIDR) inserts were applied midcycle or later. In contrast, when treatments were initiated before midcycle, conception rates were improved for cows treated with CIDR inserts for 6 or 12 d, beginning 4 to 9 d after AI compared with controls (Macmillan and Peterson, 1993). The treatment that most consistently improved conception rates in that study was a 6- or 12-d CIDR insert beginning on 6 to 8 d after AI. Furthermore, a meta-analysis of 17 P4-supplementation studies indicated treatment during the first week after AI enhances conception rates but has no effect when administered during the second or third weeks after AI (Mann and Lamming, 1999). Similar CIDR treatments administered to cows with or without an active CL increased peripheral concentrations of P4 in suckled beef cattle by 0.5 to 1 ng/mL (Stevenson et al., 2003) or only slightly in lactating dairy cattle (Stevenson et al., 2006).
Inducing accessory CL with GnRH or its agonists is well documented and forms the basis for the first GnRH injection of the Ovsynch protocol (Pursley et al., 1998). Subsequent work demonstrated that incidence of ovulation was greatest when GnRH was injected between d 5 and 12 of the estrous cycle (Vasconcelos et al., 1999). When injected on d 5 or 6, a GnRH agonist (8 µg of Buserelin) was equally effective as 3,000 IU of hCG for inducing accessory CL, but the subsequent increase in concentrations of P4 was greater in hCG-treated heifers (Schmitt et al., 1996).
We hypothesized that increasing or supplementing endogenous concentrations of P4 in lactating dairy cattle early after AI may spare embryonic loss and improve overall conception rates. Our overall objective was to investigate the effect of supplemental blood P4 and exogenous GnRH and hCG on follicular development, incidence of ovulation, serum P4, conception rate, and pregnancy survival.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Experiment 1
The purpose of experiment 1 was to assess ovarian responses to GnRH, hCG, and exogenous P4 (CIDR insert). Ovaries of 162 lactating Holstein cows housed at the Kansas State University Dairy Teaching and Research Center were scanned by using transrectal ultrasonography (5 mHz transrectal probe, Aloka 500V, Corimetrics, Wallingford, CT). Ovarian structures were mapped and sized on the day of treatment and 7 d later. The following measurements and subsequent calculations were made: 1) difference in the number of follicles
5 mm in diameter at treatment (d 0) and 7 d later; 2) size of the largest follicle 7 d after treatment; 3) percentage of cows having induced ovulation; 4) total number of CL 7 d after treatment; 5) total number of induced CL; 6) increased diameter and volume of the original CL assessed on 7 d after treatment; 7) size of follicles that ovulated; 8) total follicular volume 7 d after treatment; and 9) total luteal volume 7 d after treatment. Follicles and CL were assumed to be spherical in shape. Diameter was assessed by averaging the largest cross-sectional width and height. Volume of follicles and CL were calculated as follows:
![]() |
For all CL in which fluid cavities were detected, volume of the cavity was calculated and subtracted from the volume of the entire CL.
Blood was collected at the initiation of treatments and 7 d later to measure treatment effects on serum concentrations of P4. Cows located in the Kansas State University dairy, and at 2 commercial dairy farms in which experiment 2 was being conducted, had blood samples collected as described relative to treatments (Table 1
). Blood serum concentrations of P4 were determined by radioimmunoassay (Skaggs et al., 1986) for samples collected at treatment and 7 d later. Both samples collected from each cow were included in the same assay. Intra-and interassay coefficients of variation for 11 assays were 7.7 and 9.8%, respectively, for a pooled sample that averaged 3.9 ± 0.07 ng/mL.
|
Increases in concentrations of P4 from the onset of treatment to 7 d later (d 7 minus d 0) were compared by using ANOVA (procedure GLM; SAS Inst. Inc.). The model consisted of treatment (n = 4), herd (n = 3), lactation number (1, 2, or 3+), interactions of treatment x herd and treatment x lactation number, plus covariables including most recent test-day milk and BCS. A priori contrasts were made for each treatment vs. the control.
Experiment 2
The purpose of experiment 2 was to assess effects of treatments on conception rates and pregnancy survival. A total of 2,852 lactating Holstein cows were treated in the Kansas State University herd and at 4 commercial dairy locations (Table 1
). Projected sample sizes were based on being able to detect a 5% difference in conception rate with 85% power. Pregnancy was diagnosed by using transrectal ultrasonography or transrectal palpation (Table 1
), and pregnancy was reconfirmed in all pregnant cows 14 to 30 d later to monitor pregnancy survival.
Conception rates were calculated based on the number of pregnant cows at each diagnosis divided by the number of cows previously inseminated and treated. Resulting pregnancy survival between the first and subsequent pregnancy diagnosis was calculated. Conception rates and pregnancy survival were analyzed by using logistic regression (procedure GENMOD; SAS Inst. Inc.) with a model consisting of treatment (n = 4), lactation number (1, 2, or 3+), herd (n = 5), 2-way interactions of treatment with herd and lactation number, month of treatment nested within herd, day after AI at onset of treatment nested within herd, and most recent test-day milk, DIM, and BCS (covariables). A priori contrasts were made for each treatment vs. the control. When interactions of treatment x lactation number (1, 2, or 3+) or treatment x herd occurred, individual treatment comparisons were made with the control by
2 within lactation number or herd, respectively.
| RESULTS |
|---|
|
|
|---|
Experiment 1
Ovarian characteristics of 162 treated cows (herd 1 in Table 1
) are summarized in Table 2
. Because a large percentage of the cows eligible for treatment at 4 to 9 d after AI were previously TAI, only cows that had a CL at the first ultrasound exam that was consistent in size for that stage of the estrous cycle or pregnancy were included in experiment 1. Mean diameter of follicles just before treatment that eventually ovulated in response to GnRH or hCG did not differ. More (P < 0.01) cows treated with GnRH and hCG ovulated at least 1 follicle than controls. When only cows having at least 1 follicle
10 mm at treatment were considered, percentage of follicles that ovulated increased to 64.1 and 81.3% for GnRH and hCG cows, respectively (Table 2
). Of those cows treated with GnRH and hCG that were induced to ovulate, 74.5% ovulated 1 follicle (38 of 51), whereas 2 follicles were induced to ovulate in 12 cows (23.5%), and 3 follicles were induced to ovulate in 1 cow (2%). Ten of the 13 cows in which more than 1 follicle was induced to ovulate were treated with hCG. In 1 control and 2 cows treated with a CIDR, a new CL was detected 7 d after treatment. These CL were misidentified as a follicle or were too indistinct to visualize at the initial ovarian scan.
|
5 mm at treatment and number of induced CL was positive and linear (P < 0.05; Figure 1
5 mm at treatment.
|
Because of a large incidence of induced ovulation after treatment with GnRH or hCG, diameter of the largest follicle subsequently identified in the pair of ovaries 7 d after treatment was less (P
0.05) in cows treated with GnRH and hCG than in controls. Further, mean total follicular volume 7 d after treatment was less (P
0.05) in treated cows, compared with controls (Table 2
).
Concentrations of P4 in serum at the time of treatment and 7 d later were determined in 753 cows in 3 herds (herds 1, 2, and 4; Table 1
). As expected, concentration of P4 in serum increased (P < 0.001) from day of treatment (4 to 9 d after AI; 3.2 ± 0.1 ng/mL) until 7 d later. Increase in serum P4 from treatment to 7 d later, however, was greater (P < 0.001) in cows treated with hCG than in controls (Figure 2A
). The second set of bars in Figure 2
represents the mean change in concentrations of P4 for cows in which serum P4 was
1 ng/mL at treatment and 7 d later. Including only cows in this analysis that met this criterion probably eliminated a large proportion of cows that were not at the appropriate stage of the estrous cycle or pregnancy at onset of treatment. Based on that criterion, change in serum P4 was consistent with the previous interpretation, in which only hCG caused a greater (P < 0.001) increase in P4 than controls (Figure 2B
).
|
1 ng/mL at treatment and 7 d later was 481 of 594 (81%). A comparable proportion of cows in herd 1, which were known to be properly staged because each cow treated had a CL verified by ultrasonography, was 150 of 162 cows (92.6%). Difference in these 2 proportions indicates that approximately 12% of the cows in herds 2 and 4 may not have been treated at the designed postinsemination interval. The partial correlation between follicle diameters identified on d 0 and subsequent diameter of the induced CL forming from that follicle was 0.54 (P < 0.001). A smaller correlation was detected between follicle volume and induced CL volume (r = 0.33; P < 0.001). Relative to total luteal volume (all CL identified on d 7) in controls of herd 1, proportion of total luteal volume was 65.1, 100.6, and 149.7% for CIDR, GnRH, and hCG treatments, respectively. Similar proportions, relative to concentration of serum P4 in controls on d 7, were 97.4, 84.8, and 109.4%, respectively. The preceding proportions partly explain why the partial correlation between serum P4 concentrations on d 7 and total luteal volume was small (r = 0.15; P = 0.07).
Experiment 2
Conception rates of 2,852 cows in 5 herds described in Tables 3
and 4
were assessed by ultrasonography in 2 herds (herds 1 and 3) and by palpation per rectum of uterine contents in 3 herds (herds 2, 4, and 5). Treatment with hCG increased (P < 0.05) conception rates in herd 3. Treatment with hCG increased (P < 0.01) conception rates in second-lactation cows (Table 4
). Overall, a priori contrasts indicated that the CIDR tended (P = 0.075) to increase and hCG increased (P < 0.05) conception rates compared with controls (Table 3
).
|
|
|
Pregnancy survival is summarized in Table 4
. Survival was reduced (P < 0.05) by GnRH in cows in their third or greater lactation, compared with contemporary controls in the same lactation group. A priori contrasts indicated that pregnancy survival tended (P = 0.09) to be slightly reduced by hCG treatment and was reduced (P = 0.05) by GnRH treatment. As expected, pregnancy survival was less (P < 0.01) in the 2 herds (herd 1 = 89.4% and herd 3 = 91.6%) in which pregnancy was diagnosed earlier after AI, compared with the 3 herds in which pregnancy was confirmed later by palpation (herd 2 = 100%, herd 4 = 97.4%, and herd 5 = 97.8%). None of the other independent variables in the model significantly influenced pregnancy survival, including the most recent test-day milk yield, DIM, or BCS, except a tendency (P = 0.10) for month of treatment.
| DISCUSSION |
|---|
|
|
|---|
Greater growth of the original CL in response to hCG is consistent with the fact that hCG has activity similar to LH. Human chorionic gonadotropin is able to bind to target tissue LH receptors and mimic the effects of LH by causing small luteal cells to increase P4 synthesis. Number of small luteal cells increased approximately 5-fold from d 4 to 16 of the untreated ovine estrous cycle, with little change in cell volume, whereas large luteal cells increased in size, with little change in cell number (Niswender et al., 2000). We interpret the increase in the original CL diameter and volume in response to hCG to have resulted from changes in luteal cell populations and proportions as reported in the ovine. When given early in the ovine estrous cycle (d 3 to 5), hCG altered the proportion of small and large luteal cells, thus potentially changing total production of P4 by the CL because approximately 80% of luteal P4 is derived from large luteal cells (Niswender et al., 2000). Increased blood P4 can occur because of the effects of hCG on the existing CL or by stimulating the formation of accessory CL (Fricke et al., 1993; Schmitt et al., 1996; Santos et al., 2001). Although greater concentrations of P4 in serum were detected in hCG-treated cows in our study, the percentage increase in total luteal volume (including original and accessory CL) in response to hCG (50%) was greater than the percentage increase in serum P4 (9%), compared with controls. Corpora lutea induced by hCG on d 6 of the cycle differed in color and size from the original CL and, when cultured with LH, produced less P4 in vitro than was produced by spontaneously formed CL of comparable age (Fricke et al., 1993).
Inducing accessory CL with GnRH or its agonists is well documented and forms the basis for the first injection in the Ovsynch protocol (Pursley et al., 1998). In the present study, 100 µg of GnRH did not increase total luteal volume or serum P4 concentrations by d 7 after treatment, which is consistent with results of Sterry et al. (2006). In contrast, in lactating dairy cows treated with 100 µg of GnRH on d 5 after AI, serum P4 was greater on d 14 in 12 of 12 cows in which accessory CL were induced (Howard et al., 2006).
Although in our study GnRH seemed slightly less effective in inducing accessory CL than was hCG, a GnRH agonist (Buserelin) was equally as effective as 3,000 IU of hCG for inducing accessory CL when injected on d 5 or 6 of the cycle, but subsequent increases in concentrations of P4 were greater in hCG-treated heifers (Schmitt et al., 1996). The same dose of Buserelin, given to lactating nonpregnant or pregnant dairy cows 11 to 14 d after estrus and AI, increased serum P4 beginning 3 d after injection, and serum P4 remained greater than controls for up to 3 and 12 d, respectively (Stevenson et al., 1993). Likewise, when 100 µg of GnRH was given to lactating dairy cows at 12 h after the onset of estrus, luteal slices from their CL removed 10 d later produced more P4 in the presence of LH than did comparable luteal slices removed from control cows treated at estrus with saline (Mee et al., 1993). Further, CL from those GnRH-treated cows had a greater proportion of large luteal cells and a lesser proportion of small luteal cells. It seems that timing of administration, potency of GnRH, or both, may determine ability of GnRH to alter luteal composition and subsequent serum concentrations of P4.
Treatment of cows with CIDR inserts in the present study failed to increase concentrations of P4 in serum. Studies conducted to administer exogenous progestins during the luteal phase after insemination by applying the PRID for 6 to 12 d produced inconsistent effects on serum P4 (Robinson et al., 1989; Stevenson and Mee, 1991). Concentrations of P4 in the former study were increased when cows were treated with a PRID for 7 d between d 5 and 12, but not when treated between d 12 and 19. In other studies, CIDR inserts placed in cows during the luteal phase increased serum concentrations of P4 by only 0.5 to 1 ng/mL (Stevenson et al., 2003; Sterry et al., 2006; Stevenson et al., 2006).
Although all cows were treated once between 4 and 9 d after AI, serum P4 concentrations indicate that approximately 12% of cows may not have been treated between 4 to 9 d after estrus. Because a large percentage of cows were treated after a TAI, only the study conducted in herd 1 (experiment 1) was a true biological test of the treatments relative to days after estrus. In that herd, the CIDR insert tended to improve conception rates in a limited number of cows (n = 40) per treatment, in addition to positive conception results observed in herd 3. Percentage of cows that was properly staged (89%) is consistent with reported synchronization rates (proportion of cows in which concentrations of P4 at 48 h after PGF2
injection in an TAI protocol were similar to those found in estrual cows) in other studies (Pursley et al., 1998; Stevenson et al., 2006).
Conception rates in our study revealed a tendency for interactions of treatment with herd (P = 0.11) and lactation number (P = 0.07). Although more than 700 cows were enrolled per treatment, use of the CIDR only tended to improve conception rates, whereas hCG sig-nificantly improved conception rates. When the CIDR was used, in 2 of 5 herds tested (based on
2 tests), the CIDR improved conception rates (in 1 herd the increase was significant), whereas in 2 herds, conception rates were less than in controls (in 1 herd the decrease was significant). Although the CIDR may have improved conception rates, it seemed to do so without elevating peripheral concentrations of P4. Conception success is coincident with normal concentrations of P4 as early as d 6 after insemination, and timing and magnitude of the P4 increase generally occur earlier and reach greater concentrations in pregnant than in nonpregnant cows (Thatcher et al., 2001). Embryo development is related to concentrations of P4 and the ability of the conceptus to secrete the antiluteolytic hormone, interferon-
(Mann et al., 1999). Exogenous P4 stimulates embryo development (Thatcher et al., 1994).
In the present study, although more than 60% of the monitored cows formed accessory CL in response to treatment with GnRH once between 4 and 9 d after AI, GnRH did not increase conception rates. Failure to improve conception rates is consistent with results of another recent study in which dairy cows were treated on d 5 after estrus and AI (Howard et al., 2006). Results of a meta-analysis (Peters et al., 2000) in which cows were treated with GnRH from 11 to 14 d after AI, showed that fertility was improved in only 5 of 19 studies; when the analysis was limited to 6 studies having 5 common variables, however, GnRH treatment improved conception rates. Timing of treatment after estrus may be a critical component of the potential for GnRH to improve conception potential.
Not all studies reported improved conception rates in cattle when they were treated with hCG at various periods after AI. Conception rates in beef heifers were improved when hCG was administered on d 4 after estrus (Breuel et al., 1989) and on d 5 after AI in lactating dairy cows (Santos et al., 2001), but in at least 8 other studies, no positive effect was detected in cattle when hCG was administered in various regimens between 3 and 35 d after estrus (Rettmer, 1991). Treatment with hCG in the present study significantly improved conception rate in 1 herd and increased conception rates in second-lactation cows. Treatment success is likely related to the timing of the hCG treatment after AI and the stage of follicle maturity because lactating dairy cows treated with 1,000 IU of hCG on d 0, 7, or 14 after estrus had greater rates of accessory CL formation on d 0 (3 of 8 cows); d 7 (7 of 9 cows), and d 14 (4 of 9 cows), compared with 1 of 8 nontreated controls (Rajamahendran and Sianangama, 1992).
Overall, a significant effect of day of treatment initiation was detected in our study. Treatments with the CIDR, GnRH, and hCG initiated after d 6 consistently improved fertility compared with control. This timing is consistent with the conclusions of Macmillan and Peterson (1993) who used the CIDR. When treatments were initiated before midcycle, conception rates were improved for cows treated with CIDR inserts for 6 or 12 d, beginning 4 to 9 d after AI. The most consistent treatment, resulting in best conception rates used 7-d treatments beginning on d 6 to 8 after AI. Conclusions of the previous study are consistent with a meta-analysis of 17 P4 supplementation studies, in which treatment during the first week of pregnancy increased conception rates but provided no benefit when administered during the second and third weeks of pregnancy (Mann and Lamming, 1999).
Embryonic mortality after conception is a significant contributor to reduced conception rates in lactating dairy cattle, and growing evidence for this assertion was summarized recently (Santos et al., 2004). We had anticipated that embryo survival might improve in response to treatments in which serum P4 was increased. Because pregnancy survival was not improved between the first and second pregnancy diagnoses and improvements tended to occur in initial conception rates, only very early embryo loss was spared in CIDR and hCG cows before the first pregnancy diagnosis. Most embryo deaths occur early after fertilization (Santos et al., 2004), with 30% by d 7, 40% between d 8 and 17, and 24% between d 17 and 24 after AI. Timing of our treatments may have reduced pregnancy loss in any of these periods but most likely reduced losses before maternal recognition of pregnancy (d 14 to 17). Early embryo growth and development is stimulated by P4 (Thatcher et al., 2001), and serum P4 and conception were increased by hCG. In contrast, effects of the CIDR were not reflected by increases in serum P4. Despite this lack of increase in peripheral concentrations of P4, physiological effects on the uterus and embryo may have occurred.
Application of microionized P4 via the vagina doubled concentrations of P4 in uterine arterial blood in human females, compared with concentrations of P4 in peripheral arterial blood (Cicinelli et al., 2000). Further, concentrations of P4 in endometrial cells were 10 to 20 times greater after vaginal administration than after i.m. injections of P4 given in doses resulting in identical peripheral concentrations of P4. Results of that experiment indicate that the uterus and the embryo may be influenced by vaginal treatment with P4, even though peripheral concentrations of P4 were not elevated or were only slightly elevated.
Because the CIDR may have increased local, but not peripheral, concentrations of P4 in other reproductive tissues, and hCG increased peripheral concentrations of P4, it would be logical to speculate that improved fertility was a direct effect of P4. Although GnRH and hCG were effective (>60%) in inducing ovulation of ancillary CL, serum P4 was only elevated in the hCG-treated cows. In contrast, potential improvements in fertility were evident in hCG-treated cows, and in CIDR-treated cows, for which no increase in serum P4 was detected. Cows treated with GnRH probably had elevated serum P4 after d 7 (Howard et al., 2006), but in that study and in the present study, no fertility response was observed. This indicates that the positive effect of hCG on fertility may be independent of elevated serum concentrations of P4. If true, the mechanism whereby fertility was enhanced independent of elevated serum concentrations of P4 is unknown.
| CONCLUSIONS |
|---|
|
|
|---|
| ACKNOWLEDGEMENTS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
Received for publication June 19, 2006. Accepted for publication August 29, 2006.
| REFERENCES |
|---|
|
|
|---|
causes regression of an hCG-induced corpus luteum before day 5 of its life-span in cattle. J. Reprod. Fertil. 90:245253.[Abstract]This article has been cited by other articles:
![]() |
J. S. Stevenson, S. M. Tiffany, and E. K. Inskeep Maintenance of Pregnancy in Dairy Cattle After Treatment with Human Chorionic Gonadotropin or Gonadotropin-Releasing Hormone J Dairy Sci, August 1, 2008; 91(8): 3092 - 3101. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. O. Lemley, S. T. Butler, W. R. Butler, and M. E. Wilson Short Communication: Insulin Alters Hepatic Progesterone Catabolic Enzymes Cytochrome P450 2C and 3A in Dairy Cows J Dairy Sci, February 1, 2008; 91(2): 641 - 645. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |